Ionic Capital Management’s Immunovant IMVT Stock Holding History

Ionic Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-70,000	Closed	-$740K	–	355
2021 Q2	$740K	Buy	+70,000	New	+$977K	0.08%	217

Other funds holding IMVT

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ionic Capital Management's IMVT Position: Q3 2021 in Review

Ionic Capital Management sold out of Immunovant (IMVT) in Q3 2021, closing a stake of 70,000 shares — an estimated $740K sold.

Ionic Capital Management first reported a position in IMVT in Q2 2021 and held it in 1 quarter. The position peaked at $740K in Q2 2021. 119 funds tracked by Wall St. Rank hold IMVT as of Q3 2021.

Ionic Capital Management reported no remaining Immunovant position as of Q3 2021 after selling out during the quarter.
Ionic Capital Management sold 70,000 Immunovant shares in Q3 2021, an estimated $740K.
Ionic Capital Management first reported a position in Immunovant in Q2 2021 and held it in 1 quarter.
Ionic Capital Management's Immunovant position peaked at $740K in Q2 2021.
119 funds tracked by Wall St. Rank held Immunovant as of Q3 2021.

Based on Ionic Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.